BioIVT to Host Open House for Advanced Therapy Researchers at its New Blood Donor Centre in London, UK

BioIVT will showcase its complete range of products and services for cell and gene therapy and immuno-oncology drug developers

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting an open house from 7-9 pm on February 23. Light hors d'oeuvres will be served in a COVID-19 compliant setting at the Scale Space venue at 58 Wood Lane, London W12 7RZ. Then, BioIVT staff will give guided tours of the company’s new laboratories and blood donor center so researchers can see how the company’s high quality biospecimens are collected and processed. Attendees will quickly discover why BioIVT is perfectly positioned to be the region's local immune cell provider.

BioIVT is hosting this event to celebrate its partnership with One Nucleus, a not-for-profit life science membership group focused primarily on the Greater Cambridge and London Life Sciences Cluster in the UK. One Nucleus aims to enable that ecosystem to accelerate the translation of great science and innovation into better patient outcomes.

“This open house will provide an excellent opportunity for our members to view BioIVT’s new facilities and learn how the company has become a critical supplier of leukopaks, immune cells, and other biospecimens for medical researchers in the UK and Europe. They will discover different ways in which BioIVT can support their research and development of advanced therapeutics going forward,” said Tony Jones, CEO of One Nucleus.

“BioIVT’s new location has expanded apheresis, whole blood, and plasma collection capabilities, plus an on-site cell isolation laboratory. We have already received blood donations from more than 500 people at this new center and expect to be able to work with up to 40 donors a day. Taken together, these capabilities enable us to provide fresh, well-characterized leukopaks, immune cells, and other biospecimens to local researchers in the UK and EU, thus reducing cryopreservation and shipping costs, whilst maximizing biological relevancy,” said Trevor Smith, MS, MBA, Product Manager, Immune Cell Portfolio at BioIVT.

“BioIVT was the first company to offer UK collected leukopaks (through our Clinical Trials Laboratory Services business), and we have established our expertise as a leading provider in the region for the past four years. When required, we can also source mobilised and disease state leukopaks and immune cells from our US donor sites and global clinical collections network,” he added.

BioIVT’s broad product portfolio enables it to support cell and gene therapy research regardless of the cell type, indication, or stage of development. It also offers extensive characterization services, such as high-definition HLA typing, Fc receptor genotyping, and CMV IgG serology.

Researchers who would like to attend this event can register at https://onenucleus.com/civicrm/event/info%3Fid%3D1537%26reset%3D1. Any questions regarding registration should be directed to alicia@onenucleus.com.

About BioIVT
BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.